知镜 Cognispect · 医学文献与研究工作台

Low-Dose CT Lung-RADS 2022 for the Management of Screening- and Non-Screening-detected Lung Cancer Associated with Cystic Airspaces.

Mascalchi M, Cavigli E, Puliti D, Cortez Ibanez F, Manneschi G, Gorini G, Picozzi G, De Luca GR, Sali L, Diciotti S, Delorme S, Kaaks R.
Radiology · 2026-11-01 · PMID 43007081

文献摘要

Background Lung cancer associated with cystic airspaces (CA) can be misinterpreted as a benign lesion, leading to missed or delayed diagnosis; however, the effect of the Lung Imaging Reporting and Data System (Lung-RADS) 2022 criteria remains unverified. Purpose To retrospectively determine the frequency and outcomes of lung cancer associated with CA during screening and explore the potential effect of Lung-RADS 2022 on earlier diagnosis. Materials and Methods This secondary analysis included participants with lung cancers from three trials: the National Lung Screening Trial (2002-2007); Italian Lung Cancer Screening Trial, or ITALUNG (2004-2010); and German Lung Cancer Screening Intervention trial, or LUSI (2007-2016). Two radiologists jointly reviewed low-dose CT images to identify and morphologically characterize lung cancer associated with CA. Associations with histologic features, stage, and other variables were assessed. Lung cancer-specific survival was analyzed using Fine-Gray regression accounting for the competing risk of non-lung cancer death. Multivariable models were adjusted for age, sex, stage, detection status, and trial. Lung-RADS 2022 criteria for atypical pulmonary cysts were applied. Results Seventy-three cancers associated with CA were identified in 1258 participants (median age, 64 years [IQR, 61-69 years]; 43 male), including 44 of 716 (6.1%) screening-detected and 29 of 542 (5.4%) non-screening-detected cancers. Multilocular morphologic type was associated with a more advanced stage than unilocular morphologic type (12 of 24 vs 15 of 49; P = .02). The 5-year lung cancer-specific survival was 51.4% (95% CI: 39.3, 62.3) for cancers associated with CA and 53.2% (95% CI: 50.1, 56.2) for 1054 participants with noncystic non-small cell lung cancer. No evidence of a difference in survival was observed (subdistribution hazard ratio, 1.15 [95% CI: 0.81, 1.63]; P = .44), and results remained consistent in multivariable models. Lung-RADS 2022 might have enabled earlier diagnosis in 55 of 73 cancers associated with CA (75%). Conclusion Lung cancer associated with CA accounted for 6.1% of screening-detected and 5.4% of non-screening-detected lung cancers. Outcomes were similar to those of noncystic non-small cell lung cancer, and Lung-RADS 2022 may facilitate earlier diagnosis. Clinical trial registration nos. NCT00047385, NCT02777996, and ISRCTN N30604390 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Byrne and Hammer in this issue.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。